We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

78 hedge funds and large institutions have $639M invested in Oric Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 18

1.25% more ownership

Funds ownership: 97.24% → 98.49% (+1.3%)

5% less funds holding

Funds holding: 82 → 78 (-4)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

27% less capital invested

Capital invested by funds: $874M → $639M (-$235M)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

Holders
78
Holders Change
-4
Holders Change %
-4.88%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.07%
New
9
Increased
35
Reduced
18
Closed
13
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$981K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$9.79M
2
BlackRock
BlackRock
New York
+$7.89M
3
AG
Artal Group
Luxembourg
+$6.57M
4
Victory Capital Management
Victory Capital Management
Texas
+$4.36M
5
Morgan Stanley
Morgan Stanley
New York
+$2.92M

Top Sellers

1
ABG
Ally Bridge Group
New York
-$10.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.49M
3
SFM
Sphera Funds Management
Israel
-$4.16M
4
Jennison Associates
Jennison Associates
New York
-$3.21M
5
State Street
State Street
Massachusetts
-$2.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$97.4M +$2.63K +120 +0%
CG
2
Column Group
California
$84.3M – – –
EC
3
EcoR1 Capital
California
$54.7M – – –
O
4
OrbiMed
New York
$41.4M – – –
BlackRock
5
BlackRock
New York
$40.2M +$7.89M +359,957 +19%
Victory Capital Management
6
Victory Capital Management
Texas
$23.1M +$4.36M +198,986 +18%
State Street
7
State Street
Massachusetts
$22.1M -$2.49M -113,652 -8%
Wells Fargo
8
Wells Fargo
California
$22M +$823K +37,540 +3%
Vanguard Group
9
Vanguard Group
Pennsylvania
$21.8M -$468K -21,337 -2%
ACH
10
ArrowMark Colorado Holdings
Colorado
$18.1M -$107K -4,885 -0.5%
IFA
11
Invus Financial Advisors
New York
$17.8M – – –
Alkeon Capital Management
12
Alkeon Capital Management
New York
$17.6M -$23.5K -1,072 -0.1%
Jennison Associates
13
Jennison Associates
New York
$17.6M -$3.21M -146,534 -13%
EC
14
Euclidean Capital
New York
$17.6M – – –
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$16.7M -$7.49M -341,646 -27%
EAM
16
Eventide Asset Management
Massachusetts
$15.5M +$9.79M +446,948 +104%
EA
17
Emerald Advisers
Pennsylvania
$10.7M -$279K -12,753 -2%
MSKCC
18
Memorial Sloan Kettering Cancer Center
New York
$10.7M – – –
CC
19
Casdin Capital
New York
$10.6M – – –
RCM
20
RA Capital Management
Massachusetts
$10.3M – – –
EMFAT
21
Emerald Mutual Fund Advisers Trust
Pennsylvania
$9.86M -$1.47M -67,000 -11%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$7.21M +$1.57M +71,418 +21%
AG
23
Artal Group
Luxembourg
$7.08M +$6.57M +300,000 +300%
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$5.04M -$11K -500 -0.2%
Northern Trust
25
Northern Trust
Illinois
$4.92M +$1.03M +47,134 +20%
1
2 3 4

ORIC Hedge Fund Activity: Q2 2021 in Review

78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2021, worth a combined $639M — down 27% from $874M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ORIC and 9 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 35 added.

The largest buyer was Eventide Asset Management, adding an estimated $9.79M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $10.1M sold.

  • 78 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2021, down from 82 in Q1 2021.
  • Funds reported $639M of Oric Pharmaceuticals stock for Q2 2021, down 27% quarter-over-quarter.
  • 9 funds opened new Oric Pharmaceuticals positions in Q2 2021 and 13 closed out, a net change of -4 holders.
  • The largest Oric Pharmaceuticals buyer in Q2 2021 was Eventide Asset Management, an estimated $9.79M added.
  • The largest Oric Pharmaceuticals seller in Q2 2021 was Ally Bridge Group, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2021.